Drug intelligence / Profile preview

DWKH-R

Development stage: Phase 3
Lead developer: Daewon Pharm
Modality: Small Molecules

Overview

DWKH-R is a drug referenced in the context of clinical trials for respiratory conditions, including lung injury, pediatric common cold, and respiratory syncytial virus (RSV) infection. It was studied in a phase 3 randomized, double-blind, parallel, multicenter trial sponsored by Daewon Pharmaceutical. The specific mechanism of action, molecular modality, and active ingredient(s) for DWKH-R are not disclosed in publicly available sources as of June 2025. The trial included adults aged 19–80 and focused on efficacy and safety endpoints relevant to acute respiratory illnesses[6].

Other names: DWKH-R

Beyond the preview

Go deeper on DWKH-R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWKH-R.

Explore the full profile